Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Fig. 1

Graph showing antibody-dependent cell-mediated cytotoxicity for all five CS cell lines in control conditions and with solitomab at two effector: target ratios. The higher effector: target ratio of 1:20 exhibited more pronounced cytotoxicity results (EpCAM+ cell lines, ratio 1:10, p = 6.40731E-10, EpCAM+ cell lines, 1:20, p = 2.10467E-10). In EpCAM- cell line the difference in cytotoxicity between control Bite and solitumab was not significant)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us